Interview: Patrice Carayon – CEO, Chiesi France
Patrice Carayon, CEO of Chiesi France, reveals how Chiesi is one of a select few international mid-size pharmaceutical companies in France to have both an R&D and production footprint to…
Chiesi is an international company based in Parma, with 80 years of experience and a strong focus on research, development, production and the commercialisation of innovative medicines in the Respiratory, Neonatology, Rare Disease and Special Care Therapeutic Areas.With a turnover of more than €1.3 billion sales, Chiesi is among the top 50 pharmaceutical companies in the world. They have production sites are in Parma, Italy, Blois (France) and Santana De Parnaiba (Brazil) and R&D centres in Parma (Italy), Paris (France), Rockville (USA), Chippenham (UK).
Chiesi is one of a select few international mid-size pharmaceutical companies in France to have both an R&D and production footprint to accompany its commercial activities. In 2013 Chiesi announced an investment of 22 million euros (USD 23.90 million) in their production site in Blois. Significant investments in manufacturing capacity have been made. Previously, the site employed 60 people, by the end of 2016 this number will have almost doubled.
Chiesi was established in France in 1992 through its subsidiary ProMedica. In 1999, the Italian group strengthened its presence with the acquisition of Logeais Group. Today, the French subsidiary is directed by Patrice Carayon. It represents 8 percent of total Group sales with a turnover of 104 million euros in 2014. Subsidiary of primary importance, France is Chiesi´s fifth most important market.
Contact
Address: Immeuble le Doublon – 11 Avenue Dubonnet, 92400 Courbevoie – France
Tel: 33 1 47688899
Patrice Carayon, CEO of Chiesi France, reveals how Chiesi is one of a select few international mid-size pharmaceutical companies in France to have both an R&D and production footprint to…
The basis of the pharmaceutical business model is changing. Take sales forces for instance, what will be the composition and daily routine? How much mixed media will it require? Currently,…
Thierry Philip, president of Institut Curie, talks about the organization, the effect of cancer on Social Security and the need for a cohesive European plan involving all oncology research institutions…
Ipsen global CEO David Meek provides a fascinating look into the French pharmaceutical ecosystem, Ipsen’s bold global expansion plans, its R&D transformation, and the exciting changes to come. From…
Dr. Catherine Jessus, Director of the INSB (Institute of Biological Sciences), the largest branch of the CNRS (National Center for Scientific Research) in France, discusses the strengths and weaknesses of…
Eric Bothorel, Deputy at the French Assemblée Nationale and responsible for the parliamentary group on data, knowledge & AI, provides an exclusive interview on France’s digitalization process. Bothorel describes France’s…
Dr. Julien Borowczyk, Secretary of the Social Affairs Commission at the French Assemblée Nationale, offers his insights on the upcoming changes to the French healthcare system. He walks our audience…
Genethon, a laboratory created by the patient organization AFM-Telethon, is one of the world’s leaders in the development of biotherapies for rare diseases. In this interview Genethon’s CEO Frédéric Revah…
Philippe Lamoureux, director of LEEM, the pharmaceutical industry’s association in France, reflects on the winds of change in the sector after the establishment of the Macron government, the 2018 Strategic…
Jacques Vernin, president of FACOPHAR Santé – the French association representing companies involved in the natural and herbal health space, explains its role and the future of the organization in…
Prof. Alexis Brice, director of the French Brain & Spine Institute (Institut du Cerveau et de la Moelle épinière (ICM)), reveals the recipe behind the success of the center since…
Emmanuel Eumont, general manager of Gedeon Richter France, discusses the group’s leading position in women’s health, its external growth strategy, notably through the acquisition of Finox Biotech in 2016, and…
Dominique Martin, CEO of the ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé) provides a fascinating insight into the French process of authorizing drugs and medical…
Dr. Denis Comet, President of AFCRO (the French Association of CROs), talks about the evolution of the clinical research environment in France and the new government actions aimed at speeding…
See our Cookie Privacy Policy Here
